“…However, the 2 trials that reported HELLP syndrome as an outcome differed by more than could be expected by chance alone. 30,31,38 Comparing hydralazine with nifedipine, Kwawukume and Ghosh reported no raised liver enzymes, 38 but in a comparison of hydralazine and ketanserin, Bolte et al reported a significantly higher incidence (45% vs. 9%) of HELLP syndrome (using Sibai's definition in the hydralazine group). 30,31 In summary, hydralazine was associated with more persistent severe hypertension than nifedipine or isradipine, and more of the following outcomes when compared with all antihypertensives: maternal hypotension, placental abruption, cesarean section, and maternal oliguria.…”